Menu Search
Equities

OncoTherapy Science Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert
30O:MUN

OncoTherapy Science Inc

Actions
  • Price (EUR)0.13
  • Today's Change0.00 / 0.00%
  • Shares traded10.00
  • 1 Year change-35.00%
  • Beta0.5567
Data delayed at least 15 minutes, as of Feb 16 2026 07:06 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

OncoTherapy Science, Inc. is a Japan-based company mainly engaged in the development of drugs. The Company is involved in the development of low molecular drugs, antibody drugs and other drugs, as well as the provision and clinical development of medical candidate substances. The Company operates its business in cooperation with universities and other corporations. The Company provides its licenses to pharmaceutical manufacturers. The Company also involves in T Cell Receptor(TCR) analysis business.

  • Revenue in JPY (TTM)784.25m
  • Net income in JPY-881.65m
  • Incorporated2001
  • Employees47.00
  • Location
    OncoTherapy Science Inc1-2, Higashida-cho, Kawasaki-kuKAWASAKI-SHI 210-0005JapanJPN
  • Phone+81 442016429
  • Fax+81 442016473
  • Websitehttp://www.oncotherapy.co.jp
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.